Eli Lilly and Company $LLY Stock Position Boosted by Silver Oak Securities Incorporated

Silver Oak Securities Incorporated raised its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 373.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,966 shares of the company’s stock after acquiring an additional 17,330 shares during the quarter. Eli Lilly and Company accounts for about 1.8% of Silver Oak Securities Incorporated’s investment portfolio, making the stock its 5th largest holding. Silver Oak Securities Incorporated’s holdings in Eli Lilly and Company were worth $25,416,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Marshall & Sterling Wealth Advisors Inc. grew its holdings in Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after purchasing an additional 15 shares in the last quarter. Torren Management LLC increased its stake in Eli Lilly and Company by 357.1% during the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after buying an additional 25 shares during the period. AlphaCentric Advisors LLC acquired a new position in Eli Lilly and Company in the 1st quarter worth $42,000. Foresight Capital Management Advisors Inc. acquired a new position in Eli Lilly and Company in the 3rd quarter worth $49,000. Finally, Caitlin John LLC purchased a new position in Eli Lilly and Company in the 2nd quarter valued at about $64,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,444.05 on Monday. The firm has a market cap of $1.36 trillion, a PE ratio of 46.87, a price-to-earnings-growth ratio of 1.73 and a beta of 0.40. The firm’s 50-day simple moving average is $1,242.25 and its 200-day simple moving average is $1,110.30. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,460.00.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period last year, the firm earned $7.02 earnings per share. Equities analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.

Insider Activity at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Recent Eli Lilly and Company Headlines

Investors following LLY have been watching these headlines:

  • Positive Sentiment: China approved Lilly’s oral weight-loss drug orforglipron, marketed as Foundayo. As the first GLP-1 weight-loss pill approved in China, it gives Lilly an early foothold in a large market and could broaden access beyond injectable treatments; competition from other drugmakers remains a factor. Reuters: China approves Eli Lilly’s weight loss pill orforglipron
  • Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania manufacturing facility intended to make next-generation obesity medicines, including investigational retatrutide. The project supports the company’s broader production expansion, although the site is not expected to begin operations until 2031. Lilly announces Pennsylvania manufacturing facility
  • Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on LLY. Citigroup raised their target price on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Argus boosted their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Scotiabank increased their price target on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a report on Friday, October 30th. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research note on Friday. Finally, Bank of America restated a “buy” rating and set a $1,497.00 price objective on shares of Eli Lilly and Company in a report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,416.64.

View Our Latest Stock Report on LLY

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.